Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia

Maternal physiological hypercholesterolemia (MPH) occurs during pregnancy to assure fetal development. Some pregnant women develop maternal supraphysiological hypercholesterolemia (MSPH) characterized by increased levels of low-density lipoprotein (LDL). We aim to determine if proprotein convertase...

Full description

Bibliographic Details
Main Authors:	Claudette Cantin, María Jesús Garchitorena, Rodrigo Escalona, Jorge A. Carvajal, Sebastián E. Illanes, Jaime Gutierrez, Andrea Leiva
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Antioxidants
Subjects:	pregnancy low-density lipoproteins PCSK9 atherogenic profile
Online Access:	https://www.mdpi.com/2076-3921/11/5/869

Similar Items

Maternal Supraphysiological Hypercholesterolemia Is Accompanied by Shifts in the Composition and Anti-Atherogenic Functions of Maternal HDL along with Maternal Cardiovascular Risk Markers at Term of Pregnancy
by: Claudette Cantin, et al.
Published: (2023-09-01)

On the atherogenicity of triglyceride-rich lipoproteins and novel markers for the assessment of their atherogenic potentials
by: Alaupovic Petar
Published: (2002-07-01)

Atherogenic Index of Plasma in the Three Trimesters of Pregnancy
by: Bana K. Hamadameen, et al.
Published: (2023-11-01)

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis
by: Yi-Ting Huang, et al.
Published: (2022-04-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
by: Tina Levstek, et al.
Published: (2023-03-01)

Effect of Aqueous Extract of Walnut Leaves on Lipid Profile and Atherogenic Ratio in Hypercholesterolemic Rats
by: Rabia Azhar, Arif Siddiqui, Shazia Ali
Published: (2015-09-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
by: Rahayu Zulkapli, et al.
Published: (2023-03-01)

Atherogenic dyslipidemia
by: C N Manjunath, et al.
Published: (2013-01-01)

The atherogenic index of plasma (AIP) is a predictor for the severity of coronary artery disease
by: Ya Li, et al.
Published: (2023-06-01)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo
by: Elise F. Villard, PhD, et al.
Published: (2016-10-01)

Maternal supraphysiological hypercholesterolemia associates with endothelial dysfunction of the placental microvasculature
by: Bárbara Fuenzalida, et al.
Published: (2018-05-01)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
by: Anastasiia Yu. Filatova, et al.
Published: (2023-06-01)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
by: Tingting Li, et al.
Published: (2021-01-01)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
by: Kepa B. Uribe, et al.
Published: (2021-12-01)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
by: Jean-Philippe Drouin-Chartier, et al.
Published: (2017-06-01)

Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report
by: Ziyue Zhang, et al.
Published: (2024-03-01)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01)

Coronary heart disease and chronic kidney disease: the possibilities of PCSK9 inhibitors in the achievement of atherogenic lipoproteins target values
by: G. S. Mal, et al.
Published: (2022-06-01)

The ratio of low-density lipoprotein cholesterol to apolipoprotein-B as a marker of low-density lipoprotein particle size
by: A. M. Kaneva, et al.
Published: (2018-06-01)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
by: Giovanni Ciccarelli, et al.
Published: (2018-03-01)

Atherogenic Plasma Index or Non-High-Density Lipoproteins as Markers Best Reflecting Age-Related High Concentrations of Small Dense Low-Density Lipoproteins
by: Sylwia Płaczkowska, et al.
Published: (2022-05-01)

ASSOCIATION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Just Price for PCSK9 Inhibitors: No less, No More
by: Khurram Nasir
Published: (2018-11-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Exploring PCSK9 Genetic Impact on Lipoprotein(a) via Dual Approaches: Association and Mendelian Randomization
by: Ya-Ching Chang, et al.
Published: (2023-09-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure
by: Khalid Al-Waili, et al.
Published: (2013-01-01)

RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Association Between Atherogenic Index of Plasma and Atherogenic Coefficient and in-Stent Restenosis After Drug-eluting Stent Implantation for Stable Coronary Artery Disease
by: Yasin Yüksel, et al.
Published: (2023-02-01)

PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases
by: V Z Lankin, et al.
Published: (2018-09-01)

A Study on Atherogenic Indices of Pregnancy Induced Hypertension Patients as Compared to Normal Pregnant Women
by: Meenakshi Singh, et al.
Published: (2015-07-01)

In Vitro Effects of Cryptotanshinone on Early Atherogenic Events Induced by Oxidized Low Density Lipoprotein and Tumour Necrosis Factor-α
by: Ang, Kok Pian
Published: (2010)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
by: Tsuyoshi Yamamoto, et al.
Published: (2012-01-01)

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
by: Katja Hrovat, et al.
Published: (2022-07-01)

Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy
by: Kui Huang, et al.
Published: (2021-06-01)

Genetic Determinants of Atherogenic Indexes
by: Tomas Texis, et al.
Published: (2023-06-01)

Atherogenic index of plasma is an independent predictor of mitral annular calcification
by: Sezen Baglan Uzunget, et al.
Published: (2022-11-01)